Sign Up
OverviewAPI
The biotech industry is facing challenges in funding, IPOs, and private financing rounds. Thermo Fisher Scientific warns of a funding squeeze in the biotech sector, leading to a decline in demand for its services. Eight biotech companies raised $1.1 billion through IPOs in the third quarter, but only two traded above their debut share price. Lexeo Therapeutics and Abivax file for IPOs on the Nasdaq.

Ask a question